The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Rifater 50 mg/300 mg/120 mg Tablets



Sanofi-Aventis Ireland Limited T/A SANOFIPA0540/067/001

Main Information

Trade NameRifater 50 mg/300 mg/120 mg Tablets
Active SubstancesIsoniazid
Pyrazinamide
Rifampicin
Dosage FormTablet
Licence HolderSanofi-Aventis Ireland Limited T/A SANOFI
Licence NumberPA0540/067/001

Group Information

ATC CodeJ04AM Combinations of drugs for treatment of tuberculosis
J04AM05 rifampicin, pyrazinamide and isoniazid

Status

License statusAuthorised
Licence Issued09/02/1987
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back